EUVIMED · CrossrefJournal
Clinical Lymphoma
ISSN 1526-9655 · Elsevier BV
Latest articles
Hematological Malignancies and Pregnancy: A Final Report of 84 Children Who Received Chemotherapy In Utero
Highlights From: 44th Annual Meeting of the American Society of Hematology;December 7-10, 2002 Philadelphia, Pennsylvania
Factors Predicting the Response to Rituximab in Indolent Lymphoma
Primary Intraocular Lymphoma: Clinical Features, Diagnosis, and Treatment
Positron Emission Tomography in the Management of Patients with Indolent Non-Hodgkin's Lymphoma
Highlights From: 39th Annual Meeting of the American Society of Clinical Oncology;May 31 to June 3, 2003 Chicago, Illinois
Phase II Trials of Bortezomib (PS-341, Velcade™), a Selective Proteasome Inhibitor, in Non-Hodgkin's Lymphoma
Impact of Dose-Intense and Dose-Dense Approaches on Outcome in Aggressive Non-Hodgkin's Lymphoma
Highlights From: 45th Annual Meeting of the American Society of Hematology December 6-9, 2003 San Diego, California
Gene Expression Profiling as a Diagnostic and Prognostic Tool in B-Cell Non-Hodgkin's Lymphoma
Gemcitabine-Based Therapy in Relapsed Non-Hodgkin's Lymphoma and Cutaneous T-Cell Lymphoma
Highlights From: 45th Annual Meeting of the American Society of Hematology December 6-9, 2003 San Diego, California
New Developments with Bortezomib in Treating Multiple Myeloma
Progress with Alemtuzumab in Chronic Lymphocytic Leukemia: Update from the 2003 Meeting of the American Society of Hematology
Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia
Highlights From: 8th Annual International Congress on Hematological Malignancies March 2004 Whistler, British Columbia, Canada
Depsipeptide, a Histone Deacetylase Inhibitor, Shows Promising Clinical Activity in T-Cell Lymphomas
Activity of Gallium Nitrate in Patients with Refractory Lymphoma
Highlights From: 40th Annual Meeting of the American Society of Clinical Oncology; June 2004 New Orleans, Louisiana
Rituximab Improves Rate and Duration of Chemotherapy-Induced Remissions in Indolent and Aggressive Non-Hodgkin's Lymphoma
Can [18F]Fluorodeoxyglucose Positron Emission Tomography Replace Bone Marrow Biopsy in Staging of Malignant Lymphoma?
Non-Hodgkin's Lymphoma in the Microarray Era
Highlights From: 46th Annual Meeting of the American Society of Hematology, December 2004, San Diego, California
Optimizing the Clinical Benefit of Rituximab in Indolent Non-Hodgkin's Lymphoma
Rituximab in Aggressive Non-Hodgkin's Lymphoma: An Update of Studies Presented at the 2004 American Society of Hematology Meeting
Monoclonal Immunoglobulins and Peripheral Neuropathy: Causative Agent or Coincidental Finding?
Highlights From: 9th Annual International Congress on Hematologic Malignancies February 2005, Whistler, BC, Canada, 41st Annual Meeting of the American Society of Clinical Oncology May 2005, Orlando, FL, 46th Annual Meeting of the American Society of Hematology December 2004, San Diego, CA
Highlights From: 37th Annual American Society of Clinical Oncology Meeting, San Francisco, CA May 12–15, 2001
Phase II Trials of EPOCH/Rituximab in Patients with Aggressive Lymphomas
Commentary on “Primary Systemic Anaplastic Large-Cell Lymphoma (CD30+): Advances in Biology and Current Therapeutic Approaches”
EUVIMED